Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company dedicated to pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Their focus is on creating "off-the-shelf" CAR T cell therapies, which use T cells from healthy donors rather than the patient themselves. This approach has the potential to provide more accessible, scalable, and faster treatment options for patients.

Allogene has a robust pipeline of AlloCAR T™ products targeting various blood cancers, solid tumors, and autoimmune diseases. They are actively conducting clinical trials for these products, including the pivotal Phase 2 ALPHA3 trial for cema-cel as a frontline consolidation treatment for LBCL. Their commitment to innovation is driven by a world-class management team with significant experience in cell therapy, and their state-of-the-art manufacturing facility, Cell Forge 1, is designed to meet the future demands of producing these life-changing therapies.

Allogene Therapeutics is a clinical-stage biotechnology company dedicated to revolutionizing cell therapy by delivering the first allogeneic CAR T cell (AlloCAR T™) products for blood cancers, solid tumors and autoimmune disease. Their mission is to create and lead this revolution, making AlloCAR T™ products accessible, cost-effective, and readily available to patients, ultimately redefining the future of CAR T treatment.

Allogene Therapeutics promotes a culture of innovation, focus, collaboration, and leadership. The company values scientific advancement and encourages its employees to be innovative in their approach to finding solutions for cancer and autoimmune diseases. Allogene emphasizes teamwork and collaboration, believing that working together towards a common vision is crucial. They also encourage taking calculated risks to lead the next revolution in cell therapy.

Allogene Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace. They recognize that disease does not discriminate and neither should its treatment. The company leverages the power of diversity to unlock the best in its employees, creating an inclusive environment built on respect, collaboration, and open communication. This commitment is reflected in their active recruitment, internship, and mentorship programs, which aim to create a stronger Allogene that delivers life-changing products for patients.